GB984810A - Polypeptides - Google Patents
PolypeptidesInfo
- Publication number
- GB984810A GB984810A GB37178/62A GB3717862A GB984810A GB 984810 A GB984810 A GB 984810A GB 37178/62 A GB37178/62 A GB 37178/62A GB 3717862 A GB3717862 A GB 3717862A GB 984810 A GB984810 A GB 984810A
- Authority
- GB
- United Kingdom
- Prior art keywords
- carbobenzoxy
- seryl
- methyl ester
- tosyl
- trityl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
The invention comprises polypeptides R-L-alanyl - L - phenylalanyl - L - isoleucylglycyl- L - leucyl - L - methioninamide wherein R may be hydrogen, L-aspartyl, L-glutaminyl-L-prolyl - L - seryl - L - lipyl - L - aspartyl or L-pyroglutamyl - L - prolyl - L - seryl - L - lysyl-L-aspartyl, their salts and esters and protected derivatives e.g. the N-tosyl-, -carbobenzozy-, - carbo - t - butoxy -, - trifluoroacetyl, or - trityl - derivatives; or the methyl, ethyl, t-butyl; benzyl or p-nitrobenzyl esters, or hydrazides); the preparation thereof by condensing a derivative of L-alanyl-L-phenylalanyl-L-isoleucine having a protective group for an amino group with glycyl-L-leucyl-L-methioninamide, where appropriate condensing the hexapeptide with a derivative of aspartic acid having a protective group for an amino-group and b -carboxyl group and where appropriate condensing the resulting heptapeptide with a derivative of L - glutaminyl - L - prolyl - L-seryl - L - lysine having the amino - group protected, where appropriate eliminating ammonia from the resulting undecapeptide to yield L - pyroglutamyl - L - prolyl - L - seryl-L - lysyl - L - aspartyl - L - alanyl - L - phenyl-alanyl - L - isoleucyl - glycyl - L - leucyl - L-methioninamide and removing the protecting groups. The removal of ammonia may be effected by carboxylic acid exchange resins or heating with water. Tosyl - L - pyroglutamyl - L - proline is prepared from tosyl-L-pyroglutamyl chloride and L - proline and converted into tosyl - L - glutaminyl - L - proline by ammonia. Carbobenzoxy - L - seryl - hydrazide is converted into the azide and this was converted into carbobenzoxy - L - seryl - (e - N - tosyl) - L-lysine ethyl ester, the free dipeptide ester, N-tosyl-L - glutaminyl - L - prolyl - L - seryl - (e - N-tosyl) - L - lysine ethyl ester and the N - tosyl-tetrapeptide in stages. Carbobenzoxy-L-phenylalanine and L-isoleucine methyl ester give carbobenzoxy - L - phenylalanyl - L - isoleucine methyl ester, and this is converted in stages, into the free dipeptide ester, carbobenzoxy-L-alanyl-L - phenylalanyl - L - isoleucine methyl ester and the N - carbobenzoxy - tripeptide. Carbobenzoxyglycyl - L - leucine and methionine methyl ester give carbobenzoxyglycyl - L - leucyl - L-methionine methyl ester and in stages this is converted to the N-carboxytripeptamide and the free tripeptamide. N-Carbobenzoxy-L-pyroglutamyl-L-proline is prepared from N-carbobenzoxy - L - pyroglutamyl chloride and L - proline and is reacted with ammonia to give N-carbobenzoxy - L - glutaminyl - L - proline. N - Trityl-L-serine is prepared by tritylating serine methyl ester and hydrolysing the N-trityl ester and is converted in stages into N-trityl-L-seryl-e - N - carbobenzoxy - L - lysine methyl ester, L - seryl - e - N - carbobenzoxy - L - lipine methyl ester, N-carbobenzoxy-L-glutaminyl-L-prolyl - L - seryl e - N - carbobenzoxy - L - lipine methyl ester, and the hydrazide. N-Trityl-glycyl-L-leucine is prepared from N-trityl-glycine and L-leucine methyl ester and hydrolysing the dipeptide ester. Glycyl-L-leucyl-L-methionamide is also prepared by condensing L-methioninamide, from L-methionine ethyl ester and ammonia, with N-trityl-glycyl-L-leucine and detritylating the N-trityl-tripeptamide so formed. Hypotensive compositions comprise the compounds of the invention together with an inert carrier or diluent in dosage unit form, preferably for parenteral administration. Specification 872,332 is referred to.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1798361 | 1961-10-05 | ||
IT216162 | 1962-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB984810A true GB984810A (en) | 1965-03-03 |
Family
ID=26325222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB37178/62A Expired GB984810A (en) | 1961-10-05 | 1962-10-01 | Polypeptides |
Country Status (7)
Country | Link |
---|---|
CH (1) | CH429754A (en) |
DE (1) | DE1518133B1 (en) |
DK (2) | DK108976C (en) |
ES (1) | ES281304A1 (en) |
FR (1) | FR2822M (en) |
GB (1) | GB984810A (en) |
SE (1) | SE302617B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004017964A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
WO2007062314A2 (en) | 2005-11-23 | 2007-05-31 | Bristol-Myers Squibb Company | Heterocyclic cetp inhibitors |
WO2007105049A1 (en) | 2006-03-10 | 2007-09-20 | Pfizer Products Inc. | Dibenzyl amine derivatives as cetp inhibitors |
WO2007105050A1 (en) | 2006-03-10 | 2007-09-20 | Pfizer Products Inc. | Dibenzyl amine compounds and derivatives |
WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
EP2392567A1 (en) | 2005-10-21 | 2011-12-07 | Bristol-Myers Squibb Company | Benzothiazine derivatives and their use as lxr modulators |
WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
-
1962
- 1962-10-01 GB GB37178/62A patent/GB984810A/en not_active Expired
- 1962-10-01 DE DE19621518133 patent/DE1518133B1/en active Pending
- 1962-10-02 CH CH1155562A patent/CH429754A/en unknown
- 1962-10-03 DK DK352664AA patent/DK108976C/en active
- 1962-10-03 FR FR911147A patent/FR2822M/en not_active Expired
- 1962-10-03 DK DK428662AA patent/DK104307C/en active
- 1962-10-04 SE SE10643/62A patent/SE302617B/xx unknown
- 1962-10-04 ES ES281304A patent/ES281304A1/en not_active Expired
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004017964A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
EP2392567A1 (en) | 2005-10-21 | 2011-12-07 | Bristol-Myers Squibb Company | Benzothiazine derivatives and their use as lxr modulators |
WO2007062314A2 (en) | 2005-11-23 | 2007-05-31 | Bristol-Myers Squibb Company | Heterocyclic cetp inhibitors |
WO2007105049A1 (en) | 2006-03-10 | 2007-09-20 | Pfizer Products Inc. | Dibenzyl amine derivatives as cetp inhibitors |
WO2007105050A1 (en) | 2006-03-10 | 2007-09-20 | Pfizer Products Inc. | Dibenzyl amine compounds and derivatives |
WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
DK104307C (en) | 1966-05-02 |
ES281304A1 (en) | 1963-04-16 |
SE302617B (en) | 1968-07-29 |
FR2822M (en) | 1964-10-05 |
CH429754A (en) | 1967-02-15 |
DE1518133B1 (en) | 1970-08-20 |
DK108976C (en) | 1968-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910020030A (en) | Peptide compounds and methods for their preparation | |
ES467453A1 (en) | Untriakontapeptide with opiate activity | |
KR890014578A (en) | Peptide compound, preparation method thereof and pharmaceutical composition containing same | |
NO854516L (en) | NEW 5-AMINO-4-HYDROXYVALERYL DERIVATIVES. | |
ES8402559A1 (en) | Novel peptide compounds, a process for manufacturing them, pharmaceutical compositions containing them, and methods for treating ulcer and thrombus with them. | |
NO157935C (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE POLYPEPTIDES. | |
FI824419A0 (en) | CYCLIC OCTAPEPTIDER OCH PHARMACEUTICAL PREPARATION DAERAV, SAMT FOERFARANDE FOER DERAS FRAMSTAELLNING DERAS ANVAENDNING | |
GB984810A (en) | Polypeptides | |
Li et al. | The synthesis of L-histidyl-L-phenylalanyl-L-ornithyl-L-tryptophyl-glycine and L-histidyl-D-phenylalanyl-L-ornithyl-L-tryptophyl-glycine and their melanocyte-stimulating activity | |
Franzén et al. | Synthesis, properties, and use of N in-Boc-tryptophan derivatives | |
GB927714A (en) | New cyclic octapeptides | |
GB1109086A (en) | Polypeptides | |
ES460618A1 (en) | Peptide derivatives and pharmaceutical compositions containing same | |
GB1003176A (en) | Butyl ethers of hydroxy amino acids and peptides and derivatives thereof | |
GB992957A (en) | New decapeptides and their manufacture | |
ES403973A1 (en) | (ile3,leu4)-vasopressin analogs and intermediates | |
ES386846A1 (en) | Hydroxamic acid derivatives of alphaaminooxy carboxylic acids | |
ES457563A1 (en) | Dipeptide derivatives | |
KR890009974A (en) | New compounds | |
KR950032271A (en) | Azapeptide Derivatives | |
Johnson et al. | 735. Cyto-active amino-acids and peptides. Part X. A pentapeptide and a basic dipeptide from melphalan | |
JPS5225768A (en) | Preparation of novel pentapeptides | |
JPS5464692A (en) | Novel synthesis of peptide derivatives | |
GB1357121A (en) | Peptide enzyme inhibitors | |
Weinstein et al. | Sulfonylcarbamates as Amino Protecting Groups in Peptide Chemistry |